###begin article-title 0
Interleukin-10 Overexpression Promotes Fas-Ligand-Dependent Chronic Macrophage-Mediated Demyelinating Polyneuropathy
###end article-title 0
###begin p 1
Conceived and designed the experiments: DD AC RSA. Performed the experiments: DD AAK JS JK. Analyzed the data: DD AAK RSA. Contributed reagents/materials/analysis tools: JS AC. Wrote the paper: DD RSA.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Demyelinating polyneuropathy is a debilitating, poorly understood disease that can exist in acute (Guillain-Barre syndrome) or chronic forms. Interleukin-10 (IL-10), although traditionally considered an anti-inflammatory cytokine, has also been implicated in promoting abnormal angiogenesis in the eye and in the pathobiology of autoimmune diseases such as lupus and encephalomyelitis.
###end p 3
###begin title 4
Principal Findings
###end title 4
###begin p 5
###xml 553 560 553 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
Overexpression of IL-10 in a transgenic mouse model leads to macrophage-mediated demyelinating polyneuropathy. IL-10 upregulates ICAM-1 within neural tissues, promoting massive macrophage influx, inflammation-induced demyelination, and subsequent loss of neural tissue resulting in muscle weakness and paralysis. The primary insult is to perineural myelin followed by secondary axonal loss. Infiltrating macrophages within the peripheral nerves demonstrate a highly pro-inflammatory signature. Macrophages are central players in the pathophysiology, as in vivo depletion of macrophages using clodronate liposomes reverses the phenotype, including progressive nerve loss and paralysis. Macrophage-mediate demyelination is dependent on Fas-ligand (FasL)-mediated Schwann cell death.
###end p 5
###begin title 6
Significance
###end title 6
###begin p 7
###xml 25 30 <span type="species:ncbi:9606">human</span>
These findings mimic the human disease chronic idiopathic demyelinating polyneuropathy (CIDP) and may also promote further understanding of the pathobiology of related conditions such as acute idiopathic demyelinating polyneuropathy (AIDP) or Guillain-Barre syndrome.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Kelly1">[1]</xref>
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Mantovani1">[2]</xref>
###xml 892 895 892 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Kelly1">[1]</xref>
###xml 897 900 897 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Apte1">[3]</xref>
###xml 902 905 902 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Dace1">[4]</xref>
###xml 1377 1380 1377 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Apte1">[3]</xref>
###xml 1478 1481 1478 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Dace1">[4]</xref>
###xml 1025 1031 <span type="species:ncbi:9606">people</span>
###xml 1175 1178 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1184 1189 <span type="species:ncbi:10090">mouse</span>
###xml 1200 1203 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Macrophages carry out a wide variety of biological functions and their ultimate effector phenotype is largely dependent upon activation and polarization. Polarization, in turn, is regulated by the dominant cytokine signature in the resident tissue microenvironment [1], [2]. Macrophages can acquire a "classically-activated" phenotype (i.e. M1 macrophage) and display an anti-angiogenic, anti-bacterial, and pro-inflammatory functions; or an "alternatively-activated" phenotype (i.e. M2 macrophages) and display a pro-angiogenic and anti-inflammatory phenotype. Of the cytokines involved in macrophage polarization, the immunosuppressive cytokine interleukin 10 (IL-10) plays a highly robust role in M2 polarization. IL-10-mediated polarization of macrophages towards an M2 phenotype has a detrimental affect on the ability of macrophages to regulate abnormal angiogenesis as seen in the eye [1], [3], [4]. This has particular relevance to the eye as age-related macular degeneration (AMD), the leading cause of blindness in people over 50 years of age, is characterized by the development of abnormal blood vessels underneath the retina called choroidal neovascularization (CNV). In mouse models of CNV in AMD, IL-10 promotes pathological neovascularization by preventing macrophage infiltration into the choroid and by polarizing macrophages to a pro-angiogenic M2 phenotype [3]. IL-10 has also been shown to promote pathological angiogenesis in the retina following ischemia [4].
###end p 9
###begin p 10
###xml 290 293 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Apte1">[3]</xref>
###xml 598 601 598 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Marmorstein1">[5]</xref>
###xml 737 740 737 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Apte1">[3]</xref>
###xml 1408 1411 1408 1411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Stark1">[6]</xref>
###xml 174 189 <span type="species:ncbi:10090">transgenic mice</span>
###xml 201 207 <span type="species:ncbi:10090">murine</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
###xml 285 289 <span type="species:ncbi:10090">mice</span>
###xml 613 628 <span type="species:ncbi:10090">transgenic mice</span>
###xml 710 713 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 771 786 <span type="species:ncbi:10090">transgenic mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
###xml 1225 1240 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1275 1290 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1391 1396 <span type="species:ncbi:10090">mouse</span>
Our laboratory was interested in exploiting the pro-angiogenic and anti-inflammatory properties of IL-10 in a model of age-related macular degeneration (AMD). We constructed transgenic mice expressing murine IL-10 under the control of the human VMD2 gene promoter in B6CBAF2/J founder mice [3]. VMD2 is located on chromosome 11q13, and encodes the 585 aa protein Bestrophin. Mutations in VMD2 have been implicated in Best vitelliform macular dystrophy and AMD, and bestrophin was originally identified as being localized to the basolateral plasma membrane of retinal pigment epithelium (RPE) cells [5]. VMD2-IL10 transgenic mice expressed high levels of secreted IL-10 in the retina, and were prone to develop CNV following laser-injury [3]. After creation of VMD2-IL-10 transgenic mice, our laboratory began to backcross these mice to a C57BL/6 background. Surprisingly, IL-10 transgene-positive mice at the F5 backcross generation developed spontaneous hindlimb weakness around 3-months of age, followed by eventual paralysis. Veterinary necropsy of diseased animals revealed swollen peripheral nerves, with necrotic lesions and immune cell infiltrate. This pattern of paralysis continued through subsequent generations of transgenic mice. At the F11 backcross generation, transgenic mice were monitored for development of paralysis twice weekly, using a modified grading scale similar to mouse EAE models [6]. In this study we explore the pathobiology of the autoimmune polyneuropathy associated with transgenic IL-10 overexpression.
###end p 10
###begin title 11
Results
###end title 11
###begin p 12
###xml 99 106 99 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g001">Fig. 1A</xref>
###xml 299 306 299 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g001">Fig. 1A</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 362 366 <span type="species:ncbi:10090">mice</span>
Mice positive for the IL-10 transgene as determined by PCR analysis developed hind limb paralysis (Fig. 1A). Paralysis was restricted to hind limbs of transgene positive (Tg+) mice, as paralysis of the tail was not observed. Transgene negative (Tg-) littermates did not develop hind limb paralysis (Fig. 1A). Disease onset varied from 2-4 months of age, and Tg+ mice <2 months of age showed no overt loss of motor function.
###end p 12
###begin title 13
###xml 34 49 <span type="species:ncbi:10090">transgenic mice</span>
Disease progression in VMD2-IL-10 transgenic mice.
###end title 13
###begin p 14
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
A, Tg+ mice (n = 9) develop spontaneous hindlimb paralysis, whereas age-matched Tg- littermates (n = 5) do not develop disease. B, IL-10 overexpression observed in the testes does not significantly exacerbate disease, as male Tg+ mice (n = 5) develop similar progression of disease compared to Tg+ female mice (n = 4).
###end p 14
###begin p 15
###xml 185 188 185 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Stohr1">[7]</xref>
###xml 418 421 418 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Kramer1">[8]</xref>
###xml 935 942 935 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g002">Fig. 2A</xref>
###xml 1446 1453 1446 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g001">Fig. 1B</xref>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 174 179 <span type="species:ncbi:9606">human</span>
###xml 225 231 <span type="species:ncbi:9606">humans</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 350 356 <span type="species:ncbi:10090">murine</span>
###xml 463 468 <span type="species:ncbi:9606">human</span>
###xml 481 487 <span type="species:ncbi:10090">murine</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
###xml 537 543 <span type="species:ncbi:10090">murine</span>
###xml 572 576 <span type="species:ncbi:10090">mice</span>
###xml 609 615 <span type="species:ncbi:10090">murine</span>
###xml 656 660 <span type="species:ncbi:10090">mice</span>
###xml 870 874 <span type="species:ncbi:10090">mice</span>
###xml 929 933 <span type="species:ncbi:10090">mice</span>
###xml 1011 1015 <span type="species:ncbi:10090">mice</span>
###xml 1032 1036 <span type="species:ncbi:10090">mice</span>
###xml 1198 1202 <span type="species:ncbi:10090">mice</span>
###xml 1288 1292 <span type="species:ncbi:10090">mice</span>
###xml 1354 1358 <span type="species:ncbi:10090">mice</span>
###xml 1369 1373 <span type="species:ncbi:10090">mice</span>
###xml 1440 1444 <span type="species:ncbi:10090">mice</span>
###xml 1570 1574 <span type="species:ncbi:10090">mice</span>
As stated above, VMD2 was originally identified as being localized to RPE cells. However, subsequent data has shown that human VMD2 is expressed in multiple sites within the human body [7]. GeneAtlas analysis reveals that in humans, VMD2 is highly expressed in the nervous system, including the spinal cord and multiple areas of the brain. For mice, murine VMD2 appears to be primarily expressed in the eye and testes [8]. However, the full expression pattern of human VMD2 within murine tissues is unknown. Since human VMD2 was driving murine IL-10 expression in the Tg+ mice, we examined gene expression of murine IL-10 in multiple tissues from Tg+ sick mice compared to normal Tg- control littermates, as Tg- tissues should express baseline levels of IL-10. We found increased expression of IL-10 in the eye, sciatic nerve, spinal cord, testes, and brain of Tg+ sick mice relative to IL-10 levels in the same tissues from Tg- mice (Fig. 2A). Similar expression patterns of IL-10 were observed in Tg+ healthy mice relative to Tg- mice (data not shown). Based on studies demonstrating high VMD2 expression in the testes, and since IL-10 gene expression was 55,000 fold higher in the testes of Tg+ mice, we sought to determine if increased IL-10 gene expression in the testes of male Tg+ mice may exacerbate development of disease compared to female Tg+ mice. Male Tg+ mice developed a slightly accelerated paralysis compared to female Tg+ mice (Fig. 1B). However, these differences in progression of disease were not significant and ultimately both male and female Tg+ mice developed paralysis.
###end p 15
###begin title 16
###xml 48 63 <span type="species:ncbi:10090">transgenic mice</span>
IL-10 gene and protein expression in VMD2-IL-10 transgenic mice.
###end title 16
###begin p 17
###xml 458 462 <span type="species:ncbi:10090">mice</span>
A, Gene expression of IL-10 is upregulated in the eye, testes, brain, sciatic nerve, and spinal cord of Tg+ sick animals compared to tissues from Tg- littermates, as determined by quantitative real-time RT-PCR. B, IL-10 protein levels from the cerebrospinal fluid (CSF) significantly increase in correlation with disease progression (p</=0.002 for each stage of disease), as determined by IL-10 specific ELISA. Plasma levels of IL-10 are not elevated in Tg+ mice.
###end p 17
###begin p 18
###xml 486 493 486 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g002">Fig. 2B</xref>
###xml 913 927 913 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s001">Fig. S1B and C</xref>
###xml 993 1001 993 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s001">Fig. S1A</xref>
###xml 1099 1107 1099 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s001">Fig. S1F</xref>
###xml 1182 1196 1182 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s001">Fig. S1D and E</xref>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 197 201 <span type="species:ncbi:10090">mice</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 552 556 <span type="species:ncbi:10090">mice</span>
###xml 907 911 <span type="species:ncbi:10090">mice</span>
###xml 1093 1097 <span type="species:ncbi:10090">mice</span>
To determine if IL-10 protein levels were upregulated systemically or localized to the neural tissue micromilieu, plasma and cerebrospinal fluid (CSF) of male and female Tg+ healthy mice, Tg+ sick mice, and Tg- littermates were harvested and examined by IL-10 ELISA. We found a significant increase of IL-10 protein levels in the CSF of Tg+ healthy mice compared to Tg- littermates(p<0.001), with significantly (p = 0.002) increasing levels that correlated with development of disease (Fig. 2B). Plasma levels of IL-10 protein were not elevated in Tg+ mice, indicating that systemic levels of IL-10 do not change and suggesting that localized IL-10 expression was driving development of disease. Additionally, we examined local expression of IL-10 protein by immunohistochemistry in organs directly affected by disease. We observed increased expression of IL-10 on the sciatic nerve of Tg+ healthy and sick mice (Fig. S1B and C). IL-10 staining was not observed on Tg- sciatic nerve sections (Fig. S1A). Spinal cord expression of IL-10 appeared to be localized to the dorsal roots of Tg+ sick mice (Fig. S1F), and was not apparent on Tg- or Tg+ healthy spinal cord tissue sections (Fig. S1D and E).
###end p 18
###begin p 19
###xml 244 257 244 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3A and B</xref>
###xml 411 418 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3C</xref>
###xml 525 532 523 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3D</xref>
###xml 750 763 748 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3E and F</xref>
###xml 841 854 839 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3G and H</xref>
###xml 1306 1315 1304 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3I-L</xref>
###xml 1465 1478 1463 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3O and P</xref>
###xml 1560 1573 1558 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g003">Fig. 3M and N</xref>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 456 460 <span type="species:ncbi:10090">mice</span>
###xml 744 748 <span type="species:ncbi:10090">mice</span>
###xml 976 980 <span type="species:ncbi:10090">mice</span>
###xml 1300 1304 <span type="species:ncbi:10090">mice</span>
###xml 1347 1351 <span type="species:ncbi:10090">mice</span>
###xml 1554 1558 <span type="species:ncbi:10090">mice</span>
In order to examine the pathology of disease in VMD2-IL-10 Tg mice, histological examination of various tissues from Tg-, Tg+ healthy, and Tg+ sick mice was performed. H&E staining of the sciatic nerve from Tg- and Tg+ healthy mice was normal (Fig. 3A and B), however, Tg+ sick early (defined as having a disease score of <3) sciatic nerve tissue sections revealed a dramatic infiltration of mononuclear cells (Fig. 3C). Tg+ sick late (disease grade >/=3) mice continued to have a dramatic infiltration of mononuclear cells (Fig. 3D), and also exhibited a significant loss of sciatic nerve tissue, as evidenced by a decrease in tissue diameter. Luxol fast blue staining of sciatic nerve tissue revealed no loss of myelin in Tg- and Tg+ healthy mice (Fig. 3E and F). Conversely, Tg+ sick tissues revealed significant loss of myelin staining (Fig. 3G and H). This correlation of cell infiltrate with loss of myelin in the sciatic nerve suggested that disease progression in Tg+ mice was due to an autoimmune attack of the peripheral nerves. The central nervous system, including the brain (data not shown) and the spinal cord itself, seemed resistant to the effects of increased IL-10, as H&E staining of the spinal cord tissue revealed no evidence of cell infiltrate in Tg-, Tg+ healthy, nor Tg+ sick mice (Fig. 3I-L). The dorsal roots of Tg+ sick mice do reveal a slight "moth-eaten" appearance, and some loss of myelin staining was observed in these dorsal roots (Fig. 3O and P). No loss of myelin was observed in the spinal cords of Tg- or Tg+ healthy mice (Fig. 3M and N).
###end p 19
###begin title 20
###xml 35 50 <span type="species:ncbi:10090">transgenic mice</span>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Pathology of disease in VMD2-IL-10 transgenic mice: sciatic nerve sections from mice.
###end title 20
###begin p 21
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 276 280 <span type="species:ncbi:10090">mice</span>
###xml 483 487 <span type="species:ncbi:10090">mice</span>
###xml 599 603 <span type="species:ncbi:10090">mice</span>
###xml 878 882 <span type="species:ncbi:10090">mice</span>
H&E staining of the sciatic nerve (A-D) reveals no significant cellular infiltrate in wild-type A, Tg- littermates or B, Tg+ healthy mice. C, Tg+ mice in the early stages of disease (clinical score <3) reveal a significant infiltration of cells into the sciatic nerve. D, Tg+ mice in the late stages of disease (clinical score >/=3) reveal cellular infiltration and loss of tissue diameter. Luxol fast blue staining of the sciatic nerve E-H, reveal no demyelination in (E) wild-type mice or F, Tg+ healthy animals. G,H, Significant demyelination is observed in both Tg+ sick early and Tg+ sick late mice. I-L, H&E staining of the spinal cord reveals no significant infiltration of cells, regardless of stage of disease. M-P, Luxol fast blue staining of the spinal cord reveal no observable demyelination in M, wild-type and N, Tg+ healthy animals. O, Tg+ sick early and P, late mice both demonstrate significant demyelination of the dorsal roots of spinal cord tissue. All images acquired at 100x magnification.
###end p 21
###begin p 22
###xml 187 195 187 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s002">Fig. S2C</xref>
###xml 234 248 234 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s002">Fig. S2A and B</xref>
###xml 589 603 589 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s002">Fig. S2D and F</xref>
###xml 682 690 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s002">Fig. S2G</xref>
###xml 858 866 858 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s003">Table S1</xref>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 381 385 <span type="species:ncbi:10090">mice</span>
###xml 438 443 <span type="species:ncbi:9606">human</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
In addition to the sciatic nerve, other peripheral nerves were examined for cellular infiltrate. In nerves from the brachial plexus, significant infiltrate was observed in Tg+ sick mice (Fig. S2C), but not in Tg- or Tg+ healthy mice (Fig. S2A and B). This is interesting as no paralysis was observed in the forelimbs during the course of disease. This suggests that disease in Tg+ mice may be ascending to the forelimbs, as often seen in human CIDP, yet mice perish prior to forelimb paralysis occurs. No cellular infiltrate was observed in the femoral nerve, regardless of disease state (Fig. S2D and F). In the optic nerve, no cellular infiltration was observed in Tg+ sick mice (Fig. S2G), despite the increased expression of VMD2 and IL-10 in the eyes of these animals. A summary of tissues examined, cellular infiltration, and phenotype is displayed in Table S1.
###end p 22
###begin p 23
###xml 426 433 426 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4A</xref>
###xml 641 648 641 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4B</xref>
###xml 891 898 891 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4C</xref>
###xml 78 82 <span type="species:ncbi:10090">mice</span>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 306 310 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
###xml 576 580 <span type="species:ncbi:10090">mice</span>
###xml 819 823 <span type="species:ncbi:10090">mice</span>
To identify the cellular infiltrate observed in the sciatic nerve of Tg+ sick mice, tissues from Tg- and Tg+ sick mice were harvested and flow cytometry was used to identify various immune cells, including macrophages (F4/80), monocytes (Cd11b), T cells (CD3), and neutrophils (Gr1). Spleens from Tg+ sick mice revealed decreased macrophages (p<0.001) and increased T cell populations (p = 0.008) compared to Tg- littermates (Fig. 4A). The sciatic nerve of Tg+ sick mice revealed a significant infiltration of macrophages (p = 0.001) and monocytes (p = 0.002) compared to Tg- mice, but no difference in neutrophils (p = 0.469) was observed (Fig. 4B). These results suggest that there is recruitment of macrophages from the spleen to these tissues. Although not evident in H&E staining, spinal cord tissue from Tg+ sick mice had a significant infiltration of macrophages (p = 0.002) as well (Fig. 4C), which likely corresponds to cellular infiltration into the dorsal roots and not actual cord tissue.
###end p 23
###begin title 24
###xml 34 49 <span type="species:ncbi:10090">transgenic mice</span>
Cellular infiltrate in VMD2-IL-10 transgenic mice.
###end title 24
###begin p 25
###xml 162 166 <span type="species:ncbi:10090">mice</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 368 372 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
###xml 872 876 <span type="species:ncbi:10090">mice</span>
A, Flow cytometry of spleens from animals reveal a slightly decreased presence of F4/80+ macrophages (p<0.001) and increased CD3+ T cells (p = 0.008) in Tg+ sick mice compared to Tg- littermates. B, Flow cytometry of sciatic nerve tissue from mice reveal a significant infiltration of F4/80+ (p = 0.001) and CD11b+ cells (p = 0.002) into the sciatic nerve of Tg+ sick mice compared to Tg- mice. C, Flow cytometry of spinal cord tissue reveals an increase in F4/80+ cells (p = 0.002) into the spinal cord of Tg+ sick mice. Sciatic nerve sections (200X) from mice were stained with APC conjugated anti-F4/80 antibody reveal no infiltration of F4/80+ macrophages in D, wild-type or E, Tg+ healthy animals. Significant infiltration of macrophages is seen in F, Tg+ sick early mice. Decreased macrophages and loss of tissue are observed in sciatic nerves from G, Tg+ sick late mice.
###end p 25
###begin p 26
###xml 224 237 224 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4D and E</xref>
###xml 355 362 355 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4F</xref>
###xml 449 456 449 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4G</xref>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:10090">mice</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 569 573 <span type="species:ncbi:10090">mice</span>
Additionally, sciatic nerve tissue sections were stained with APC-conjugated anti-F4/80 antibody and examined by confocal microscopy. Tg- and Tg+ healthy mice exhibited no infiltration of macrophages into the sciatic nerve (Fig. 4D and E). Tg+ sick early mice exhibited abundant macrophages in the sciatic nerve, virtually infiltrating the entire tissue (Fig. 4F). Sciatic nerve tissue from Tg+ sick late mice demonstrated infiltrating macrophages (Fig. 4G), although to a much lesser degree than Tg+ sick early tissues. Again, tissue loss was evident in Tg+ sick late mice. This, combined with the above observation of macrophages infiltrating the sciatic nerve at the time of disease suggested that macrophage-mediated demyelination of the sciatic nerve and subsequent loss of tissue resulted in clinical disease.
###end p 26
###begin p 27
###xml 419 426 419 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g005">Fig. 5A</xref>
###xml 580 587 580 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g005">Fig. 5B</xref>
###xml 931 938 927 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g005">Fig. 5C</xref>
###xml 1121 1124 1117 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Lee1">[9]</xref>
###xml 1126 1130 1122 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Wogensen1">[10]</xref>
###xml 1311 1315 1307 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Wogensen1">[10]</xref>
###xml 1574 1581 1570 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g006">Fig. 6A</xref>
###xml 1715 1728 1711 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g006">Fig. 6B and C</xref>
###xml 1824 1831 1820 1827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g006">Fig. 6D</xref>
###xml 1881 1888 1877 1884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g006">Fig. 6E</xref>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 741 745 <span type="species:ncbi:10090">mice</span>
###xml 925 929 <span type="species:ncbi:10090">mice</span>
###xml 1040 1055 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1347 1351 <span type="species:ncbi:10090">mice</span>
###xml 1613 1617 <span type="species:ncbi:10090">mice</span>
###xml 1818 1822 <span type="species:ncbi:10090">mice</span>
###xml 1859 1863 <span type="species:ncbi:10090">mice</span>
###xml 1988 1992 <span type="species:ncbi:10090">mice</span>
To determine the gene expression cytokine profile of various disease-affected tissues, spleen, sciatic nerve, and spinal cord tissue from Tg+ healthy and sick mice were harvested and examined for various pro- and anti-inflammatory cytokines by quantitative real-time PCR. Using Tg+ healthy tissues as a baseline comparison, Tg+ sick early and sick late spleens exhibited very little change in cytokine gene expression (Fig. 5A). Sciatic nerves, however, exhibited a primarily pro-inflammatory cytokine profile, with cytokine expression levels increasing with disease progression (Fig. 5B). These cytokines include FasL, IFN-gamma, and IL-12. The anti-inflammatory marker arginase (Arg1) was also increased in sciatic nerve tissues from sick mice, suggesting a possible attempt to squelch this burst of autoimmune activity. Pro- and anti-inflammatory cytokine gene expression is also evident in spinal cord tissue of Tg+ sick mice (Fig. 5C), albeit at drastically reduced levels compared to the sciatic nerve tissue. Pancreas specific IL-10 transgenic mice have been shown to develop spontaneous inflammation and diabetes [9], [10]. Cellular infiltration into the pancreas correlated with increased expression of adhesion molecules on pancreatic endothelium, including intercellular adhesion molecule 1 (ICAM-1) [10]. To determine if VMD2-IL-10 Tg mice exhibited increased ICAM-1 expression, sciatic nerve and spinal cord tissues sections were stained with PE-conjugated anti-ICAM-1 antibody. Tg- littermates exhibit no expression of ICAM-1 on sciatic nerve tissue sections (Fig. 6A), whereas Tg+ healthy and sick mice demonstrated significant staining of ICAM-1 antibody on the surface of the sciatic nerve tissue (Fig. 6B and C). Increased ICAM-1 expression was not evident on spinal cord dorsal roots in Tg+ healthy mice (Fig. 6D), but was evident once Tg+ mice develop disease (Fig. 6E). No increase in ICAM-1 expression was observed in the cerebellum of Tg-, Tg+ healthy, or Tg+ sick mice (data not shown), reflecting that sites spared of cellular infiltration lack ICAM-1 expression.
###end p 27
###begin title 28
###xml 73 88 <span type="species:ncbi:10090">transgenic mice</span>
Inflammatory gene expression profiles of various tissues from VMD2-IL-10 transgenic mice.
###end title 28
###begin p 29
###xml 20 24 <span type="species:ncbi:10090">mice</span>
A, Spleens from Tg+ mice reveal relatively low expression of pro-inflammatory cytokines, with the exception of increased FasL in Tg+ sick early spleens. B, Sciatic nerve tissues, however, demonstrate multiple cytokines with increased gene expression, both pro-inflammatory (FasL, IL-12, IFN-g) and anti-inflammatory (Arg1). C, Spinal cord tissues have few cytokines with increased expression, and only at late stages of disease.
###end p 29
###begin title 30
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
ICAM-1 expression in VMD2-IL-10 transgenic mice.
###end title 30
###begin p 31
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 256 260 <span type="species:ncbi:10090">mice</span>
###xml 329 333 <span type="species:ncbi:10090">mice</span>
Sciatic nerve sections from A, Tg- mice demonstrate no ICAM-1 expression, yet B, Tg+ healthy and C, Tg+ sick sciatic nerve sections reveal significant expression of ICAM-1 on the outer surface of the sciatic nerve. D, Spinal cord sections from Tg+ healthy mice reveal no expression of ICAM-1, yet the dorsal roots of E, Tg+ sick mice eveal positive staining of ICAM-1.
###end p 31
###begin p 32
###xml 1439 1446 1439 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g007">Fig. 7A</xref>
###xml 1613 1626 1613 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g007">Fig. 7B and C</xref>
###xml 18 33 <span type="species:ncbi:10090">transgenic mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 598 602 <span type="species:ncbi:10090">mice</span>
###xml 1339 1343 <span type="species:ncbi:10090">mice</span>
###xml 1453 1457 <span type="species:ncbi:10090">mice</span>
In our VMD2-IL-10 transgenic mice, it appears that disease progression correlated with infiltration of macrophages into the sciatic nerve and subsequent demyelination. However, paralysis can be initiated by a variety of mechanisms other than antecedent demyelination. In addition, although mice did not clinically demonstrate evidence of weakness or paralysis prior to demyelination, it remained possible there was some subclinical axonal dysfunction prior to initiation of demyelination. This includes inherent neuronal defects resulting in neuromuscular dysfunction. In order to determine if Tg+ mice have underlying axonal dysfunction prior to development of paralysis, we first stained sciatic nerve tissue sections with an antibody specific for normal neurofilament phenotype. The SMI-31 antibody reacts with a phosphorylated epitope in extensively phosphorylated neurofilament H and, to a lesser extent, with neurofilament M, a sign of normal neurofilament status. SMI 31 reacts broadly with thick and thin axons and some dendrites such as basket cell dendrites, but not Purkinje cell dendrites. Nerve cell bodies are generally unreactive, and other cells and tissues are unreactive except for peripheral axons. Damage to neurofilaments results in dephosphorylation of neurofilaments, and thus less reactivity with SMI-31. Wild-type mice demonstrated significant positive staining with SMI-31, reflecting a healthy axonal phenotype (Fig. 7A). Tg+ mice developed progressively decreased staining with SMI-31 as they developed weakness and paralysis reflecting axonal damage and loss with onset of paralysis (Fig. 7B and C).
###end p 32
###begin title 33
###xml 31 46 <span type="species:ncbi:10090">transgenic mice</span>
Neural phenotype of VMD2-IL-10 transgenic mice.
###end title 33
###begin p 34
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
A, Tg- sciatic nerve sections are strongly reactive with the SMI-31 antibody, indicating normal neurofilament phosphorylation and phenotype. B, Sciatic nerve sections from 3 month-old Tg+ mice demonstrate decreased reactivity with SMI-31, indicating a decreased loss of neurofilament in the early stages of disease prior to observable levels of cellular infiltration. C, Tg+ sick sciatic nerve sections, however, demonstrate even less reactivity with SMI-31, indicating dephosphorylation of neurofilaments and neural loss correlating with cellular infiltration. D, Voluntary wheel running (VWR) experiments with Tg+ mice (n = 3) before cellular infiltration and disease onset (3-months old) reveals no loss of motor function (distance p = 0.320; time p = 0.341; speed p = 0.576) prior to macrophage infiltration compared to age-matched Tg- littermates (n = 3).
###end p 34
###begin p 35
###xml 513 520 513 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g007">Fig. 7D</xref>
###xml 625 632 625 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g007">Fig. 7B</xref>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
###xml 555 559 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 939 943 <span type="species:ncbi:10090">mice</span>
We next examined whether the loss of neurofilament staining observed in Tg+ mice correlated with a loss of activity at times preceding macrophage infiltration and hind limb paralysis. This was done by examining voluntary wheel running (VWR) of Tg+ mice and their Tg- age-matched littermates. Three month-old Tg+ mice, prior to developing clinical signs of weakness or motor dysfunction, showed no significant difference in VWR compared to Tg- littermates, as determined by distance, time, and speed on the wheel (Fig. 7D). This demonstrates that although mice at 3 months of age demonstrate decreased neurofilament staining (Fig. 7B), loss of function in these animals does not progress until cellular infiltration and demyelination occurs, indicating that macrophages are the primary mediators of disease in Tg+ mice. This also demonstrates that paralysis and/or loss of activity is not due to an inherent neurological dysfunction in Tg+ mice.
###end p 35
###begin p 36
###xml 827 835 823 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s002">Fig. S2I</xref>
###xml 1073 1080 1069 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g002">Fig. 2B</xref>
###xml 34 49 <span type="species:ncbi:10090">transgenic mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 665 668 <span type="species:ncbi:10116">rat</span>
###xml 1056 1071 <span type="species:ncbi:10090">transgenic mice</span>
Disease progression in VMD2-IL-10 transgenic mice appears to develop in two stages. First, overexpression of IL-10 results in upregulation of ICAM-1 on sciatic nerve tissue. Secondly, macrophages infiltrate sciatic nerve tissue, cause demyelination, neuronal dysfunction, and ultimately paralysis. We wanted to test whether the onset of disease could be delayed or disease severity ameliorated by attempting to remove important components of disease progression: IL-10 and macrophages. We first attempted to block IL-10 protein expression with blocking antibodies to IL-10. Tg+ mice were treated with intraperitoneal injections of 250 microg anti-IL-10 antibody or rat IgG control antibody i.p. 1-2x weekly. Anti-IL-10 immunotherapy did not successfully delay progression of disease compared to isotype control administration (Fig. S2I). Higher doses of anti-IL-10 were not successful and resulted in toxicity (data not shown). The lack of success with i.p. administration of anti-IL-10 was not surprising, as systemic levels of IL-10 were not elevated in transgenic mice (Fig. 2B). Moreover, systemically delivered antibodies would not readily cross blood-brain barriers and penetrate nerve tissues.
###end p 36
###begin p 37
###xml 262 266 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Fraser1">[11]</xref>
###xml 485 492 477 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g008">Fig. 8A</xref>
###xml 1036 1044 1024 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007121.s002">Fig. S2H</xref>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
###xml 768 772 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
We next attempted to ameliorate disease by depletion of macrophages with clodronate liposomes. Tg+ mice were treated with intraperitoneal injections of clodronate or PBS liposomes (200 microl initial injection; 100 microl each subsequent injection) twice weekly [11]. Liposome treatment commenced immediately prior to onset of disease (day 100). Tg+ mice treated with clodronate liposomes developed paralysis at a significantly reduced tempo compared to PBS liposome-treated Tg+ mice (Fig. 8A). Clodronate liposome treatment was continued for 2 months, and ceased at day 162 due to toxicity related to repeated liposome injection. At time of cessation, the clinical score of paralysis was 1.5+/-0.41 for clodronate treated mice compared to 3.75+/-0.96 for PBS-treated mice. PBS liposome-treated Tg+ mice continued to live past day 162, suggesting that toxicity is directly attributable to the clodronate and not to liposomes. Clodronate-liposome treatment resulted in significantly reduced macrophage infiltrate into the sciatic nerve (Fig. S2H).
###end p 37
###begin title 38
###xml 113 128 <span type="species:ncbi:10090">transgenic mice</span>
Macrophage mediated disease and Fas ligand-mediated cytotoxicity of myelin-producing Schwann cells in VMD2-IL-10 transgenic mice.
###end title 38
###begin p 39
###xml 574 577 574 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</sup>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
###xml 578 582 <span type="species:ncbi:10090">mice</span>
###xml 696 700 <span type="species:ncbi:10090">mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
A, Depletion of macrophages in Tg+ mice by administration of clodronate liposomes i.p. twice weekly (n = 6) results in significant delayed onset of disease compared to PBS liposome-treated Tg+ mice (n = 5). B, Tg+ macrophages and Schwann cells were co-cultured in the presence of anti-FasL antibodies or isotype control. Cytotoxicity of Schwann cells is observed with macrophages + IgG, yet cytotoxicity is significantly decreased when FasL is blocked *(p = 0.0035). Antibodies alone do not induce Schwann cell cytotoxicity. C. VMD2-IL-10 Tg+ mice were bred with C57BL/6-Faslpr mice, which harbor a spontaneous mutation in Fas that prevents Fas-FasL interaction and signaling. Tg+ lpr homozygous mice failed to develop progressive disease and paralysis compared to Tg+ mice.
###end p 39
###begin p 40
###xml 117 130 117 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g004">Fig. 4A and B</xref>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Kelly1">[1]</xref>
###xml 188 191 188 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Apte1">[3]</xref>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Griffith1">[12]</xref>
###xml 642 646 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Jadus1">[13]</xref>
###xml 846 847 846 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1163 1170 1163 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g008">Fig. 8B</xref>
###xml 1353 1360 1353 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1406 1409 1406 1409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</sup>
###xml 1527 1530 1527 1530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 1540 1541 1540 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</italic>
###xml 1621 1628 1621 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007121-g008">Fig. 8C</xref>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 736 742 <span type="species:ncbi:10090">murine</span>
###xml 1385 1389 <span type="species:ncbi:10090">mice</span>
###xml 1410 1414 <span type="species:ncbi:10090">mice</span>
###xml 1542 1546 <span type="species:ncbi:10090">mice</span>
###xml 1615 1619 <span type="species:ncbi:10090">mice</span>
###xml 1762 1766 <span type="species:ncbi:10090">mice</span>
It was previously observed that gene expression of FasL was upregulated in the spleen and sciatic nerve of Tg+ mice (Fig. 4A and B). Since membrane bound FasL can regulate cell death [1], [3], [12], we hypothesized that this increase in FasL may be due to increased expression on Tg+ macrophages, and that these macrophages are utilizing FasL to mediate myelin-producing Schwann cell death in the sciatic nerve, leading to demyelination of the sciatic nerve and ultimately paralysis of the animal. To determine if Tg+ macrophages utilize FasL to induce Schwann cell death, a modified macrophage/target-cell co-culture experiment was utilized [13]. Macrophages from Tg+ sick mice were isolated and co-cultured with radioactively labeled murine Schwann cells at an effector:target ratio of 10:1. Schwann cell death was determined by the release of 3H-thymidine into the cell supernatant. The co-culture was performed with anti-FasL blocking antibodies or isotype control antibodies present. Tg+ macrophages induced significant Schwann cell cytotoxicity, and was due to FasL mediated death, as blocking antibodies to FasL significantly inhibited Schwann cell death (Fig. 8B). Therefore, macrophages-mediated cytotoxicity of myelin-producing Schwann cells through FasL-dependent pathways. To determine if FasL was indeed causing demyelination and paralysis in vivo, we bred VMD2-IL-10 Tg+ mice with C57BL/6-Faslpr mice, which harbor a spontaneous mutation in Fas that prevents Fas-FasL interaction and signaling. We found that Tg+ lpr homozygous mice failed to develop progressive disease and paralysis compared to Tg+ mice (Fig. 8C), confirming that Fas expression on neural tissues is necessary for macrophage- and FasL-mediated demyelination and paralysis in Tg+ mice.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Diamond1">[14]</xref>
In conclusion, VMD2-driven transgenic expression of IL-10 results in macrophage recruitment and FasL-mediated demyelination of the sciatic nerve, axonal death, and ultimately paralysis. Although IL-10 is an immunosuppressive cytokine at normal levels, overexpression of IL-10 exacerbates inflammation. IL-10 upregulates the adhesion molecules ICAM-1, that causes increased trafficking of inflammatory macrophages into the sciatic nerve via CD11b expressed on the macrophage surface, a receptor for the ligand ICAM-1[14].
###end p 42
###begin p 43
###xml 361 364 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Kelly1">[1]</xref>
###xml 366 369 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Mantovani1">[2]</xref>
###xml 869 872 865 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
Macrophages and sciatic nerve tissue in Tg+ sick mice exhibit a markedly pro-inflammatory gene expression profile, as evident by upregulated expression of FasL, IFN-gamma, and IL-12. This contrasts with the known effect of IL-10 as an immunosuppressive cytokine that polarizes macrophages towards an anti-inflammatory and pro-angiogenic gene expression profile [1], [2]. Cytokines observed at these timepoints provide an overall "snapshot" of the cytokine milieu of Tg+ sick mice at early and late stages. Also, comparisons with Tg+ healthy mice rather than Tg- mice provide a representation of disease progression in Tg+ mice rather than comparing Tg+ mice with a wild-type phenotype. Increased expression of FasL may be the cause of demyelination and tissue loss, as Tg+ macrophages induced death of myelin-producing Schwann cells in a FasL-dependent manner, and Tg+ lpr homozygous mice failed to develop progressive disease.
###end p 43
###begin p 44
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Adorini1">[15]</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Pennline1">[16]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Persson1">[17]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Powrie1">[18]</xref>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Cannella1">[19]</xref>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Nagelkerken1">[20]</xref>
###xml 779 783 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Croxford1">[21]</xref>
It has been considered that IL-10 may be a potential therapeutic in the treatment of autoimmune diseases [15]. Administration of recombinant IL-10 (rIL-10) reduces disease severity in experimental models of diabetes, rheumatoid arthritis, and inflammatory bowel disease [16], [17], [18]. However, the outcome of rIL-10 therapy in autoimmune diseases of the nervous system is unclear. In models of experimental autoimmune encephalomyelitis (EAE), intravenous injection of rIL-10 exacerbated disease [19], while subcutaneous administration of rIL-10 reduced disease severity [20]. Targeting delivery of IL-10 to the central nervous system does not increase the success of IL-10 treatment, as intracranial injection of soluble rIL-10 or plasmids encoding IL-10 did not suppress EAE [21]. Therefore, administration and/or localization of IL-10 may be critical in determining its immunoregulatory function in autoimmune diseases of the nervous system.
###end p 44
###begin p 45
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Ferguson1">[22]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Niederkorn1">[23]</xref>
###xml 806 811 <span type="species:ncbi:9606">human</span>
In our VMD2-IL-10 transgenic animals, IL-10 is not only upregulated in the sciatic nerve, but also the eye, brain, spinal cord, and especially the testes. However, our disease phenotype is restricted primarily to the sciatic nerve, and to a much lesser extent the caudal spinal cord. One hypothesis for why other organs are spared immune mediated destruction may be the immune privileged environment that these tissues possess. The eye, brain, and spinal cord are well known immune privileged sites, and possess various anti-inflammatory and pro-apoptotic molecules that may dampen an immune response in these tissues [22], [23]. Also, as the disease progresses from early stages to late stages, cellular infiltration and/or demyelination may be ascending from lower limbs to upper extremities, similar to human CIDP. This may explain while caudal spinal cord and brachial plexus nerves are not affected until later stages of disease. However, the effect of cellular infiltration into these tissues at these later stages on disease phenotype is not fully understood.
###end p 45
###begin p 46
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-MeyerzuHorste1">[24]</xref>
###xml 647 651 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-MeyerzuHorste1">[24]</xref>
###xml 1267 1271 1267 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-MeyerzuHorste1">[24]</xref>
###xml 97 103 <span type="species:ncbi:9606">humans</span>
###xml 172 177 <span type="species:ncbi:9606">human</span>
###xml 392 397 <span type="species:ncbi:9606">human</span>
###xml 550 554 <span type="species:ncbi:10116">rats</span>
###xml 906 911 <span type="species:ncbi:10090">mouse</span>
###xml 934 939 <span type="species:ncbi:10090">mouse</span>
###xml 1062 1067 <span type="species:ncbi:9606">human</span>
###xml 1355 1359 <span type="species:ncbi:10090">mice</span>
Polyneuropathies are a common neurological disease that affects the peripheral nervous system in humans. The use of animal models has helped to recapitulate and understand human neuropathies, however the transfer of treatment modalities from preclinical to clinical settings has been highly unsuccessful [24]. This may be due to the fact that established animal models do not precisely mimic human disease. For example, experimental autoimmune neuritis (EAN), the most widely used model of Guillain-Barre syndrome (GBS), involves the immunization of rats with peripheral myelin homogenates, myelin proteins, or derived peptides to produce disease [24]. This results in a primarily T cell mediated attack and demyelination of the peripheral nerves. GBS, however, results from macrophages serving as the primary effector cells in the demyelination of the peripheral nervous system. The VMD2-IL-10 transgenic mouse model may be a useful mouse model for the study of GBS pathogenesis and treatment. Animal models of CIDP have been extremely problematic in mimicking human disease. EAN models are acute, with disease recovery occurring substantially by 28 days. Other animal models for CIDP involve repeated myelin immunization that may be combined with immunosuppression [24]. These models are not ideal, as they are primarily performed in species other than mice, hampering the use of genetic knockout animals.
###end p 46
###begin p 47
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Salomon1">[25]</xref>
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 364 369 <span type="species:ncbi:9606">human</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 512 527 <span type="species:ncbi:10090">transgenic mice</span>
###xml 544 549 <span type="species:ncbi:10090">mouse</span>
Interestingly, a mouse model of CIDP has been previously demonstrated in B7-2 deficient non-obese diabetic (NOD) mice [25]. This animal model results in the infiltration of T cells and dendritic cells into the peripheral nervous system. However, disease progression was not congruent between both sexes, and cellular infiltration lacked macrophages as observed in human CIDP. In addition, autoimmune disease in these mice was manifested on two genetic backgrounds with preexisting immunodeficiencies. VMD2-IL-10 transgenic mice may be an ideal mouse model for the study of the pathobiology of CIDP and may be an excellent surrogate to investigate therapeutic options in this disease.
###end p 47
###begin title 48
Materials and Methods
###end title 48
###begin title 49
Ethics Statement
###end title 49
###begin p 50
All work was carried out in accordance with Association for Research in Vision and Ophthalmology (ARVO) guidelines. Comprehensive protocols of animal care and experimental design outlined in this study are on file and have been approved by the Washington University Committee on the Humane Care of Laboratory Animals (CHCLA). All animal caretakers and laboratory personnel have appropriate approvals based on specific AALAC-approved training programs. The facilities are inspected at regular intervals by a local University Committee and by unannounced visits directed by the Federal Government.
###end p 50
###begin title 51
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 51
###begin p 52
###xml 71 82 71 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pVMD2-placF</italic>
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VMD2</italic>
###xml 292 295 292 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Apte1">[3]</xref>
###xml 639 679 639 679 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; GGA CTT TAA GGG TTA CTT GGG TTG CC 3&#8242;</named-content>
###xml 691 730 691 730 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CAT TTT GAT CAT CAT GTA TGC TTC T 3&#8242;</named-content>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 148 153 <span type="species:ncbi:9606">human</span>
###xml 237 240 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 343 348 <span type="species:ncbi:10090">mouse</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
VMD2-IL-10 transgenic (Tg) mice were constructed to overexpress IL-10 (pVMD2-placF was provided by Noriko Ezumi, Johns Hopkins Medical School). The human VMD2 promoter was removed and cloned into the pCI plasmid (Promega), replacing the CMV promoter, and then placed the IL-10 ORF downstream [3]. Tg mice were produced by injecting fertilized mouse oocytes with transgene DNA by standard protocols in the Washington University Department of Ophthalmology and Visual Science Molecular Biology Core facility. B6CBAF2 founders were screened by PCR and used for backcrossing to C57BL/6 mice. IL-10 expression was verified by RT-PCR (forward - 5' GGA CTT TAA GGG TTA CTT GGG TTG CC 3'; reverse - 5' CAT TTT GAT CAT CAT GTA TGC TTC T 3'). Transgene-negative littermates were used as wild-type control mice.
###end p 52
###begin p 53
###xml 11 14 11 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</sup>
###xml 11 14 11 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>lpr</sup></italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 305 308 305 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lpr</italic>
###xml 15 19 <span type="species:ncbi:10090">mice</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
C57BL/6-Faslpr mice were purchased from Jackson Laboratories (Bar Harbor, ME) and bred with VMD2-IL-10 Tg+ mice. The resulting F1 offspring were screened for lpr (according to Jackson Laboratory instructions) and Tg+ (as described above) status, and Tg+ lpr heterozygous mice were bred. F2 generation Tg+ lpr homozygous offspring were identified by PCR and monitored for disease progression.
###end p 53
###begin title 54
Clinical score of paralysis
###end title 54
###begin p 55
Disease severity was scored as: grade 0, normal; grade 1, partial paralysis of 1 hind limb; grade 2, complete paralysis of 1 hind limb; grade 3, partial paralysis of both hind limbs; grade 4, complete paralysis of both hind limbs; grade 5, moribund or death. Data is reported as mean+/-SEM.
###end p 55
###begin title 56
Immunohistochemistry
###end title 56
###begin p 57
###xml 160 165 <span type="species:ncbi:10090">mouse</span>
###xml 227 232 <span type="species:ncbi:10090">mouse</span>
###xml 290 293 <span type="species:ncbi:10116">Rat</span>
###xml 299 304 <span type="species:ncbi:10090">mouse</span>
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
###xml 456 460 <span type="species:ncbi:9925">goat</span>
###xml 466 471 <span type="species:ncbi:10090">mouse</span>
5-microm paraffin embedded sections were stained with Hematoxylin and Eosin (H&E), Luxol fast blue myelin specific stain, allophycocyanin (APC)-conjugated anti-mouse F4/80 (BM8; eBioscience), phycoerythrin (PE)-conjugated anti-mouse CD54 (anti-ICAM-1; N1/1.7.4; eBioscience), PE-conjugated Rat anti-mouse IL-10 (BD Biosciences), or mouse anti-phosphorylated neurofilament antibody (SMI-31; Covance) followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG1 (Caltag). All antibodies were used at 1 microg/ml. Staining was examined by confocal microscopy (Zeiss LSM 510).
###end p 57
###begin title 58
Flow cytometry
###end title 58
###begin p 59
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 264 269 <span type="species:ncbi:10090">mouse</span>
###xml 325 330 <span type="species:ncbi:10090">mouse</span>
Single-cell suspensions from spleens, sciatic nerves, and spinal cords from wild-type and transgene-positive sick mice were obtained and stained with PE-conjugated IgG2a (eBM2a; eBioscience), PE-conjugated anti-mouse F4/80 (BM8; eBioscience), FITC-conjugated anti-mouse CD3e (1 45-2C11; eBioscience), or FITC-conjugated anti-mouse Cd11b (M1/70; BD Biosciences). Cells were then assessed for fluorescence in a FACScan flow cytometer (BD Biosciences) and the results were analyzed using Cellquest software (BD Biosciences).
###end p 59
###begin title 60
Enzyme-linked immnosorbent assay (ELISA)
###end title 60
###begin p 61
###xml 63 67 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-DeMattos1">[26]</xref>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 242 247 <span type="species:ncbi:10090">mouse</span>
Cerebrospinal fluid (CSF) was collected from the cisterna magna[26], and plasma was sampled via cardiac bleed from wild-type, transgenic healthy, and transgenic sick mice. CSF and plasma samples were then assayed for IL-10 protein levels via mouse IL-10 Quantikine ELISA kit (R&D Systems). CSF and plasma from 3 separate animals for each group were assayed.
###end p 61
###begin title 62
Quantitative Analysis of Gene Expression (Quantitative Real-Time RT-PCR)
###end title 62
###begin p 63
###xml 91 94 91 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Kelly1">[1]</xref>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
Relative expression of various inflammatory proteins were performed as previously described[1]. Tissues examined were whole spleens, sciatic nerve tissue, and spinal cord tissue from VMD2-IL-10 Tg + healthy, early sick (grade <3), and late sick (grade >/=3) mice.
###end p 63
###begin p 64
###xml 309 313 <span type="species:ncbi:10090">mice</span>
Taqman Gene Expression Assay Mixes used (primer/probe sets) include beta-actin (Mm00607939_s1); TNF-alpha (Mm00443258_m1); IL-6 (Mm00446190_m1); IL-12 (Mm01288989_m1); FasL (Mm00438864_m1); IL-1beta (Mm00434228_m1); IFN-gamma (Mm00801778_m1); and Arg1 (Mm00475988_m1). Tissues from transgene-positive healthy mice were used as a baseline comparison
###end p 64
###begin title 65
Voluntary Wheel-Running (VWR)
###end title 65
###begin p 66
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were tested after being segregated to individual cages with a voluntary exercise wheel recorded by an automatic speedometer. After a 5-day acclimation period, two 24 h running periods were recorded for speed, total distance, and total time on the wheel.
###end p 66
###begin title 67
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo anti-IL-10 antibody treatment
###end title 67
###begin p 68
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 69 72 <span type="species:ncbi:10116">rat</span>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
###xml 143 146 <span type="species:ncbi:10116">Rat</span>
VMD2-IL-10 Tg + mice were treated with intraperitoneal injections of rat anti-mouse IL-10 blocking antibody (250 microg; JES5.2A5; Genzyme) or Rat IgG (250 microg; Equitech-Bio). Injections were administered 1-2 times weekly beginning on day 50. Paralysis was monitored upon day of injection.
###end p 68
###begin title 69
Liposome-encapsulated dichloromethylene diphosphonate
###end title 69
###begin p 70
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-VanRooijen1">[27]</xref>
Multilamellar liposomes were prepared as described previously [27]. The cytotoxicity of C12MDP-LIP and PBS-LIP were tested for in vitro toxicity against RAW 264.7 macrophages before use. Liposomes were stored at 4degreesC for up to 1 month.
###end p 70
###begin title 71
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro macrophage-mediated cytotoxicity assay
###end title 71
###begin p 72
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Jadus1">[13]</xref>
###xml 296 297 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 391 392 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 537 541 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007121-Hai1">[28]</xref>
###xml 120 126 <span type="species:ncbi:10090">murine</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
Utilizing a modified version of a macrophage/target cell cytotoxicity assay from previously published reports [13], the murine Schwann cell line, SW10 (ATCC), was grown at the proliferative temperature of 33degreesC. SW10 cells were trypsinized, washed, and resuspended in DMEM media with 8 muCi 3H-thymidine add per 10 ml media. Cells were then plated in 96-well round-bottom plates at 1x104 cells/well at 37degreesC and allowed to adhere for 24 hours. This temperature prevents Schwann cell proliferation but induces myelin production [28]. Splenic macrophages from Tg+ sick mice were isolated by magnetic separation as described above. Schwann cells were washed and macrophages were added and allowed to co-culture for 24 hours. After incubation, cells were lightly centrifuged and 100 microl of supernatant was removed and placed in 2 ml scintillation fluid. Spontaneous release was determined by Schwann cells incubated with no macrophages, and maximum release was determined by lysis of cells with Qiagen lysis buffer RLT. Specific release was determined by the equation:
###end p 72
###begin p 73
Co-cultures of macrophages and Schwann cells were performed in the presence of blocking antibodies to FasL or Hamster IgG (10 microg/ml; eBioscience). Also, Schwann cells alone were incubated with antibodies to ensure no antibody-mediated cytotoxicity.
###end p 73
###begin p 74
Cytotoxicity data from quintuplicate cultures are presented as the mean+/-SD.
###end p 74
###begin title 75
Statistics
###end title 75
###begin p 76
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
A student's t test was performed for statistical analysis. A p value of <0.05 was considered significant.
###end p 76
###begin title 77
Supporting Information
###end title 77
###begin p 78
###xml 48 63 <span type="species:ncbi:10090">transgenic mice</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
IL-10 gene and protein expression in VMD2-IL-10 transgenic mice. A, Tg- and B-C, Tg+ mice reveal increased IL-10 expression on the outer surface of the sciatic nerve. Spinal cord sections (200X) from D, Tg- and E-F, Tg+ reveal increased IL-10 on the dorsal roots of Tg+ mice only after development of disease.
###end p 78
###begin p 79
(0.45 MB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
###xml 375 379 <span type="species:ncbi:10090">mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 725 729 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
Additional peripheral nerve sections and anti-IL-10 treatment. No immune cell infiltration is observed in the A, brachial plexus of Tg - or B, Tg+ healthy mice. Cellular infiltration is observed in Tg+ sick mice C, despite the lack of disease phenotype in the forelimbs. Immune cell infiltrate is not observed in the femoral nerves of D, Tg-, E, Tg+ healthy, and F, Tg+ sick mice. G, Optic nerve sections from Tg+ sick late mice do not reveal infiltration of immune cells despite increased VMD2 and IL-10 expression. H, Sciatic nerve sections from clodronate-liposome treated Tg+ mice at day 162 reveal cellular infiltrate, yet at significantly decreased levels. I, Anti-IL-10 immunotherapy (250 mg i.p. twice weekly) of Tg+ mice (n = 4) does not decrease disease onset compared to isotype control treated Tg+ mice (n = 3).
###end p 81
###begin p 82
(0.73 MB TIF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Summary of cellular infiltration and disease phenotype in various nervous tissues from VMD2-IL-10 Tg- and Tg+ mice.
###end p 84
###begin p 85
(0.04 MB DOC)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
The authors would like to thank Christina Stevens (University of Texas Southwestern Medical Center in Dallas) for liposome preparation, Paul Golumbek (Washington University in St. Louis) for voluntary wheel running (VWR) equipment and advice, and Susan Culican (Washington University in St. Louis) for brachial nerve harvesting and advice.
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice.
###end article-title 89
###begin article-title 90
Macrophage polarization comes of age.
###end article-title 90
###begin article-title 91
###xml 44 50 <span type="species:ncbi:10090">murine</span>
Macrophages inhibit neovascularization in a murine model of age-related macular degeneration.
###end article-title 91
###begin article-title 92
Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development.
###end article-title 92
###begin article-title 93
Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium.
###end article-title 93
###begin article-title 94
Differential expression of suppressors of cytokine signaling-1 and -3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis.
###end article-title 94
###begin article-title 95
###xml 12 17 <span type="species:ncbi:9606">human</span>
Three novel human VMD2-like genes are members of the evolutionary highly conserved RFP-TM family.
###end article-title 95
###begin article-title 96
###xml 36 42 <span type="species:ncbi:10090">murine</span>
Cloning and characterization of the murine Vmd2 RFP-TM gene family.
###end article-title 96
###begin article-title 97
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Pancreatic IL-10 induces diabetes in NOD.B6 Idd3 Idd10 mice.
###end article-title 97
###begin article-title 98
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans.
###end article-title 98
###begin article-title 99
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Circulation of human hematopoietic cells in severe combined immunodeficient mice after Cl2MDP-liposome-mediated macrophage depletion.
###end article-title 99
###begin article-title 100
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege.
###end article-title 100
###begin article-title 101
Macrophages kill T9 glioma tumor cells bearing the membrane isoform of macrophage colony stimulating factor through a phagocytosis-dependent pathway.
###end article-title 101
###begin article-title 102
ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18).
###end article-title 102
###begin article-title 103
Cytokine-based immunointervention in the treatment of autoimmune diseases.
###end article-title 103
###begin article-title 104
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse.
###end article-title 104
###begin article-title 105
###xml 119 123 <span type="species:ncbi:10116">rats</span>
Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats.
###end article-title 105
###begin article-title 106
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells.
###end article-title 106
###begin article-title 107
IL-10 fails to abrogate experimental autoimmune encephalomyelitis.
###end article-title 107
###begin article-title 108
###xml 115 119 <span type="species:ncbi:10090">mice</span>
IL-4 abrogates the inhibitory effect of IL-10 on the development of experimental allergic encephalomyelitis in SJL mice.
###end article-title 108
###begin article-title 109
Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system.
###end article-title 109
###begin article-title 110
Cell death and immune privilege.
###end article-title 110
###begin article-title 111
See no evil, hear no evil, do no evil: the lessons of immune privilege.
###end article-title 111
###begin article-title 112
From bench to bedside-experimental rationale for immune-specific therapies in the inflamed peripheral nerve.
###end article-title 112
###begin article-title 113
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice.
###end article-title 113
###begin article-title 114
###xml 85 90 <span type="species:ncbi:10090">mouse</span>
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease.
###end article-title 114
###begin article-title 115
The liposome-mediated macrophage 'suicide' technique.
###end article-title 115
###begin article-title 116
Comparative analysis of Schwann cell lines as model systems for myelin gene transcription studies.
###end article-title 116
###begin p 117
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 117
###begin p 118
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was supported in part by NIH Grant K08EY016139 (R.S.A.), NIH Vision Core Grant P30 EY 02687, Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award (R.S.A.), RPB Career Development Award (R.S.A.), Research to Prevent Blindness Inc. Unrestricted Grant, American Federation for Aging Research Grant (R.S.A.), International Retinal Research Foundation (R.S.A.), The American Retina Foundation (ARF), The Knights Templar Eye Foundation, Inc. (D.S.D.) and the International Retinal Research Foundation Alston Callahan Scholar Award (D.S.D.; A.A.K.).
###end p 118

